The major regulatory challenge for biosimilars is to prove that there are sufficiently similar to the innovator biologic such that the safety and efficacy are comparable. The similarity of two molecules is determined using the comparability exercise with four key parameters being addressed: safety, efficacy, quality and biological activity which are established. The choice […]